|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Analyst Conference Summaries |
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Verastem
|
2023 | |||
Verastem Q4 2022 press release |
Verastem Q1 2023 press release |
Verastem Q2 2023 press release |
|
March 14, 2023 | May 9, 2023 | Aug. 8, 2023 | |
2022 | |||
Verastem Q4 2021 press release |
Verastem Q1 2022 press release |
Verastem Q2 2022 press release |
Verastem Q3 2022 press release |
March 28, 2022 | May 9, 2022 | August 8, 2022 | Nov. 3, 2022 |
2021 | |||
Verastem Q4 2020 press release |
Verastem Q1 2021 press release |
Verastem Q2 2021 press release |
Verastem Q3 2021 press release |
March 18, 2021 | May 11, 2021 | Aug. 2, 2021 | Nov. 4, 2021 |
2020 | |||
Verastem Q4 2019 |
Verastem Q1 2020 |
Verastem Q2 2020 |
Verastem Q3 2020 press release |
Feb. 28, 2020 | May 7, 2020 | Aug. 10, 2020 | Nov. 9, 2020 |
2019 | |||
Verastem Q4 2018 |
Verastem Q1 2019 |
Verastem Q2 2019 |
Verastem Q3 2019 |
March 12, 2019 | May 9, 2019 | August 1, 2019 | Oct. 29, 2019 |
2018 |
|||
March 13, 2018 |
May 3, 2018 |
August 8, 2018 |
Nov. 7, 2018 |
Verastem (VSTM) is a commercial-stage biotechnology company specializing in cancer therapies.
More Analyst Conference Pages:
AGEN |
AGIO |
ALNY |
ALXN |
AMAT |
AMGN |
APRE |
ARWR |
BIIB |
CLDX |
CLSN |
CELG |
EPZM |
GILD |
GLYC |
ILMN |
INCY |
INO |
ISRG |
MCHP |
PLX |
REGN |
RNA |
SAGE |
SGEN |
TTPH |
VBLT |
VRTX |
XLRN |
Disclaimer: My analyst summaries may include both condensations of statements made by company representatives and my own analysis. They are not covered by any warranty. I cannot guarantee anything said by company representatives is true. I try not to make errors, but it is possible. These are my personal notes which I share with other investors and which I use as the basis of my blog and Seeking Alpha articles.
Copyright 2022 William P. Meyers